

# IQVIA Continuous Glucose Monitoring

Enhancing glucose data collection and study participation

## The Situation



**4.2 million** deaths were caused by diabetes (2019)


Source: International Diabetes Federation  
2019 data reported in 2020



**463 million** (2019)  
**700 million** (2045)  
Estimated people with diabetes worldwide

Increasing need for **integrated, flexible and real-time** continuous glucose data for safety & more effective and safer antidiabetic agents

## The Challenges



## The Solution

Intelligent Continuous Glucose Monitoring (CGM) Connections Powered by IQVIA Connected Devices



### FAST INITIATION & INTEGRATION

Rapid deployment of connected CGM devices and training allows fast activation of remote data collection. Our platform provides the ability to have a single view across CGM, Cardiac Safety, and eCOA data for deeper insights and integration.



### IMPROVED EXPERIENCE & SAFETY

Real-time, dynamic data assessment reduces burden and delivers a better experience for sites, sponsors and subjects by driving proactive treatment decisions, increased adherence, fewer required SMBG measurements and data acceptability reports, powered by a commitment to global regulatory compliance.



### ACCELERATED DEVELOPMENT & REDUCED RISK

Our Diabetes Center of Excellence, experienced staff and comprehensive connected device portfolio are integrated to help you design and integrate your trial into one platform, increasing efficiencies to get you from proof of principle to market faster.



### STREAMLINED PROCESS & INCREASED ROI

The ability to support a broad range of statistical analysis (MAGE, MOD, TIR, etc.) coupled with the option to integrate multiple connected devices (ECG, Actigraphy, Spirometry, ABMP, etc.) provides amplified data impact and an increased ROI for current and future research.

### THE VALUE PROMISE

IQVIA Continuous Glucose Monitoring offers a more complete and dynamic view of the daily measures of glucose levels and variability than the traditional measures of glucose control by self-monitored blood glucose (SMBG) and HbA1c, promoting enhanced patient safety and clinical outcomes. Our innovative platform – combined with leading operational and therapeutic expertise – captures, cleans and analyzes glucose data, enabling meaningful compound differentiation to progress clinical research forward.



### Proven expertise that matters

- Trial design – broad and deep expertise maximizes your probability of success
- Sites – dedicated training and support from IQVIA therapeutic/device experts
- Sites – access to 24/7 helpdesk with CGM-trained staff supporting 215 languages
- Access – increase research participation access to reach a broader, more diverse patient population



### Integrated technology that delivers


- Subjects insert a tiny glucose-sensor wire just under the skin using an automatic applicator to continuously measure glucose levels
- Robust CGM and BGM device portfolio and manufacturing relationships
- Industry-leading connected devices digital platform delivering advanced data integration and management
- Single, aggregated view offering customizable reports, visualizations and interface



### Services & solutions to streamline your path

- Protocol consulting and writing
- Data capture, cleaning and reporting
- Project management
- 24/7 CGM-specific lab operations
- Medical monitoring
- Analysis planning, production, interpretation and authoring
- Full-service or standalone capabilities

### Example CGM trend graph



Providing CGM and connected devices support for clinical trials since 2016

>200 diabetes Phase I-IV clinical studies since 2011



IQVIA has provided >23K CGM devices to support clinical development in 36 countries since 2016